Fukushima Tatsuya, Hozumi Akira, Tomita Masato, Yonekura Akihiko, Miyata Noriaki, Miyamoto Takashi, Taguchi Kenji, Goto Hisataka, Tsuda Keiichi, Osaki Makoto
Biomed Res. 2016;37(3):215-20. doi: 10.2220/biomedres.37.215.
Our previous study has shown that plasminogen activator inhibitor 1 (PAI-1) gene expression and secretion from bone marrow adipocytes increased markedly with dexamethasone administration. The purpose of the present study was to measure the secretion of various adipokines from human bone marrow and blood, and investigate how adipokine secretion changes in a steroid environment. Human blood and bone marrow fluid were collected from a steroid treatment group and a control group during hip replacement surgery, and an enzyme-linked immunosorbent assay (ELISA) was used to measure the adiponectin, leptin, and PAI-1 levels. Adiponectin and leptin showed no significant differences between bone marrow and blood levels, but PAI-1 was significantly higher in bone marrow. The steroid treatment group had higher levels of leptin and PAI-1 in both the blood and bone marrow than the control group. PAI-1 was present at high concentrations in the bone marrow and increased by steroid treatment. High levels of PAI-1 in bone marrow may influence intraosseous hemodynamics and may induce necrotic bone disorders.
我们之前的研究表明，给予地塞米松后，骨髓脂肪细胞中纤溶酶原激活物抑制剂1（PAI-1）的基因表达和分泌显著增加。本研究的目的是检测人骨髓和血液中各种脂肪因子的分泌情况，并研究在类固醇环境中脂肪因子分泌如何变化。在髋关节置换手术期间，从类固醇治疗组和对照组采集人血液和骨髓液，采用酶联免疫吸附测定（ELISA）法检测脂联素、瘦素和PAI-1水平。脂联素和瘦素在骨髓和血液中的水平无显著差异，但骨髓中的PAI-1水平显著更高。类固醇治疗组血液和骨髓中的瘦素和PAI-1水平均高于对照组。PAI-1在骨髓中以高浓度存在，且经类固醇治疗后增加。骨髓中高水平的PAI-1可能影响骨内血流动力学，并可能诱发坏死性骨疾病。
